Aerovate Therapeutics Inc (AVTE)

Finanzdaten der Aerovate Therapeutics Inc-Aktie (AVTE)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	-	-	-	-	-
Operating Expenses	11.57% 24.62	22.07	21.37	20.34	17.64
Operating Income/Loss	11.57% -24.62	-22.07	-21.37	-20.34	-17.64
Income/Loss From Continuing Operations Before Tax	13.90% -23.19	-20.36	-19.56	-19.02	-16.52
Income/Loss From Continuing Operations After Tax	13.58% -23.19	-20.41	-19.56	-19.02	-16.52
Net Income/Loss	13.58% -23.19	-20.41	-19.56	-19.02	-16.52
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	5,949% 27.80	0.4595	27.64	25.17	24.78
Diluted Average Shares	5,949% 27.80	0.4595	27.64	25.17	24.78
Basic Earnings Per Share	12.16% -0.83	-0.74	-0.71	-0.76	-0.67
Diluted Earnings Per Share	12.16% -0.83	-0.74	-0.71	-0.76	-0.67
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-